

PÅrr Hallberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8839751/publications.pdf>

Version: 2024-02-01

38
papers

1,090
citations

471509

17
h-index

414414

32
g-index

39
all docs

39
docs citations

39
times ranked

1786
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease. <i>Clinical and Translational Science</i> , 2022, , .	3.1	3
2	Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors. <i>Journal of the American College of Cardiology</i> , 2021, 78, 696-709.	2.8	10
3	Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate. <i>Pharmacogenomics</i> , 2021, 22, 973-982.	1.3	6
4	High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis. <i>Frontiers in Genetics</i> , 2020, 11, 951.	2.3	4
5	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. <i>Genes</i> , 2020, 11, 1275.	2.4	6
6	Exome Sequencing Reveals Common and Rare Variants in <i>F5</i> Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1195-1202.	4.7	18
7	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020, 20, 770-783.	2.0	22
8	<i>MTHFR</i> , <i>TYMS</i> and <i>SLCO1B1</i> polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2020, 21, 337-346.	1.3	8
9	SWEDEGENE—a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2020, 20, 579-585.	2.0	9
10	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	2.5	18
11	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	4.7	58
12	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	4.7	52
13	Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1226-1232.	1.9	24
14	A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture. <i>Calcified Tissue International</i> , 2019, 105, 51-67.	3.1	16
15	A Missense Variant in <i>PTPN22</i> is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
16	Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival. <i>EBioMedicine</i> , 2019, 40, 595-604.	6.1	39
17	Lateral fixation: an alternative surgical approach in the prevention of complete atypical femoral fractures. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2018, 28, 299-304.	1.4	11
18	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 843-853.	4.7	18

#	ARTICLE	IF	CITATIONS
19	Clinical factors predicting drug-induced liver injury due to flucloxacillin. Drug, Healthcare and Patient Safety, 2018, Volume 10, 95-101.	2.5	8
20	Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681881516.	1.8	3
21	Common variation near IRF6 is associated with IFN- γ -induced liver injury in multiple sclerosis. Nature Genetics, 2018, 50, 1081-1085.	21.4	32
22	Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. Pharmacogenomics, 2017, 18, 201-213.	1.3	24
23	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174
24	Reduced obstacles, maximized vision (ROMV): a new technique to facilitate laryngoscopy for endotracheal intubation. Upsala Journal of Medical Sciences, 2017, 122, 68-69.	0.9	1
25	Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough. Annals of Pharmacotherapy, 2017, 51, 293-300.	1.9	16
26	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	2.2	41
27	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes and Endocrinology, 2016, 4, 507-516.	11.4	78
28	Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database. Annals of Pharmacotherapy, 2016, 50, 616-624.	1.9	19
29	Mortality After Atypical Femoral Fractures: A Cohort Study. Journal of Bone and Mineral Research, 2016, 31, 491-497.	2.8	26
30	Entrapment of soft tissue: a new technique to improve the stability of malar augmentation with hydroxyapatite. British Journal of Oral and Maxillofacial Surgery, 2016, 54, 826-827.	0.8	3
31	Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 100.	0.4	4
32	Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates. Rheumatology, 2014, 53, 1911-1913.	1.9	12
33	Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw. Annals of the Rheumatic Diseases, 2014, 73, 1594-1594.	0.9	16
34	Digoxin and mortality in atrial fibrillation: a prospective cohort study. European Journal of Clinical Pharmacology, 2007, 63, 959-971.	1.9	102
35	Transforming growth factor β 1 genotype and change in left ventricular mass during antihypertensive treatment—results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (Silvhia). Clinical Cardiology, 2004, 27, 169-173.	1.8	11
36	Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. BMC Cardiovascular Disorders, 2003, 3, 11.	1.7	17

#	ARTICLE	IF	CITATIONS
37	The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Journal of Hypertension, 2002, 20, 2089-2093.	0.5	80
38	Molecular Genetic Screening in Patients With ACE Inhibitor/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes. Frontiers in Genetics, 0, 13, .	2.3	4